Abstract
Matrix metalloproteinases (MMPs) are implicated in the tissue destruction associated with inflammatory demyelinating diseases such as multiple sclerosis. The effect of a hydroxamate inhibitor of MMPs, Ro31-9790, on inflammatory demyelination was assessed in two acute models of experimental allergic encephalomyelitis (EAE). Daily intraperitoneal injections of Ro31-9790 (50mgkg−1), beginning either at the time of disease induction or from day 3 post induction, significantly reduced the clinical severity of adoptively transferred EAE. Administration of the inhibitor from the day of induction of active EAE prevented disease onset in 9/10 animals. However, in a repeat study, in which clinical disease was much more severe in the vehicle treated animals, the inhibitor was less effective. Clinical signs and CNS histopathology correlated well, with greater numbers of inflammatory lesions associated with increased disease severity. The present study confirms a role for the MMP cascade in inflammation in EAE.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lassmann H. Comparative Neuropathology of Chronic Experimental Allergic Encephalomyelitis and Multiple Sclerosis. Berlin:Springer-Verlag, 1983;9–37.
Rosenberg GA, Kornfeld M, Estrada E, Kelly RO, Liotta LA, Stetler-Stevenson WG. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 1992;576:203–7.
Ogata Y, Pratta MA, Nagase H, Arner EC. Matrix metalloproteinase-9 (92 kDa gelatinase type-IV collagenase) is induced in rabbit chondrocytes by cotreatment with interleukin 1β and a protein kinase C activator. Exp Cell Res 1992;201:245–9.
Dayer J-M, Beutler B, Cerami A. Cachectin tumour necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163–8.
Masure S, Proost P, Van Damme J, Opdenakker G. Purification and identification of 91-KDa neutrophil gelatinase: Release by the activating peptide interleukin-8. Eur J Biochem 1991;198:391–8.
Lacraz S, Isler P, Vey E, Welgus HG, Dayer J-M. Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J Biol Chem 1994;269:22027–33.
Cammer W, Bloom BR, Norton WT, Gordon S. Degradation of basic protein in myelin by neutral proteases secreted by stimulated macrophages: A possible mechanism of inflammatory demyelination. Proc Natl Acad Sci USA 1978;75:1554–8.
Cuzner ML, Davison AN, Rudge P. Proteolytic enzyme activity of blood leukocytes and cerebrospinal fluid in multiple sclerosis. Ann Neurol 1978;4:337–44.
Alvord EC, Hruby S, Sires LR. Degradation of myelin basic protein by cerebrospinal fluid: preservation of the antigenic determinants under physiological conditions. Ann Neurol 1979;6:474–82.
Inuzuka TY, Sato S, Baba H, Miyatake T. Neutral protease in cerebrospinal fluid from patients with multiple sclerosis and other neurological diseases. Acta Neurol Scand 1987;76:18–23.
Gijbels K, Proost P, Masure S, Carton H, Billiau A, Opdenakker G. Gelatinase B is present in the cerebrospinal fluid during experimental autoimmune encephalomyelitis and cleaves myelin basic protein. J Neurosci Res 1993;36:432–40.
Proost P, Van Damme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Comm 1993;192:1175–81.
Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992;41:29–34.
Gijbels K, Steinman L. Gelatinase B producing cells in multiple sclerosis lesions. J Cell Biochem Suppl 18D, 1994: 143.
Sibley WA, Kiernat J, Laguna JF. The modification of experimental allergic encephalomyelitis with epsilon aminocaproic acid. Neurol 1978;28:102–5.
Bronan CF, Cammer W, Norton WT, Bloom BR. Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis. Nature 1980;285:235–7.
Smith ME, Amaducci LA. Observations on the effects of protease inhibitors on the suppression of experimental allergic encephalomyelitis. Neurochem Res 1982;7:541–54.
Inuzuka T, Sato S, Baba H, Miyatake T. Suppressive effect of camostat mesilate (FOY 305) on acute experimental allergic encephalomyelitis (EAE). Neurochem Res 1988;13:225–8.
Dunkley PR, Carnegie PR. Isolation of myelin basic proteins. In: Marks N, Rodnight R, eds. Research Methods in Neurochemistry vol. 2, New York: Plenum Press, 1974:219–45.
Brown PA. Matrix metalloproteinase inhibitors in arthritis. In Osteoarthritis: Advances in Pathobiology, Diagnosis and Treatment. London: International Business Communications 1994:1–10.
Gijbels K, Galardy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 1994;94:2177–82.
Gearing AJH, Beckett P, Christodoulou M, Churchill M, et al. Processing of tumour necrosis factor-α precursor by metalloproteinases. Nature 1994;370:555–7.
McGeehan GM, Becherer JD, Bast RC, Boyer CM, et al. Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor. Nature 1994;370:558–61.
Gould KE, Stepaniak JA, Swanborg RH. Variable susceptibility of Lewis rats to experimental allergic encephalomyelitis. J Neuroimmunol 1994;54:145–6.
Leonard JP, MacKenzie FJ, Patel HA, Cuzner ML. Hypothalamic noradrenergic pathways exert an influence on neuroendocrine and clinical status in experimental autoimmune encephalomyelitis. Brain Behav Immun 1991;5:328–38.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hewson, A.K., Smith, T., Leonard, J.P. et al. Suppression of experimental allergic encephalomyelitis in the Lewis rat by the matrix metalloproteinase inhibitor Ro31-9790. Inflamm Res 44, 345–349 (1995). https://doi.org/10.1007/BF01796266
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01796266